Private Coverage of Methadone in Outpatient Treatment Programs

Daniel Polsky, Samantha Arsenault, Francisca Azocar

Research output: Contribution to journalArticle


Among the three medications approved for the treatment of opioid use disorder, methadone has been in use for the longest period and has the most extensive evidence base of effectiveness. Yet it remains underutilized as new insurance policies favor access to buprenorphine and neglect to dismantle barriers to obtaining methadone. In the absence of wholesale regulatory change, private insurance carriers should take the lead in expanding access to this medication. We offer several solutions for private payers, including expanding coverage, removing prior authorization, addressing out-of-pocket costs, increasing provider reimbursement, and incentivizing system integration.

Original languageEnglish (US)
Pages (from-to)303-306
Number of pages4
JournalPsychiatric services (Washington, D.C.)
Issue number3
StatePublished - Mar 1 2020



  • Drug abuse
  • Insurance
  • Methadone

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this